Amporin
Basel, CH · 1 known investors
Amporin is a Swiss biotech developing oral small-molecule drugs that target toxic membrane pores formed by misfolded protein oligomers in degenerative diseases such as Parkinson's, Alzheimer's, and Type 2 diabetes. Its approach repairs cellular and mitochondrial membranes to slow disease progression, with early drug discovery programs led by an α-synuclein pore-targeting candidate for Parkinson's.
BiotechDeep Tech
Investors · 1
Frequently asked questions
- What does Amporin do?
- Amporin is a Swiss biotech developing oral small-molecule drugs that target toxic membrane pores formed by misfolded protein oligomers in degenerative diseases such as Parkinson's, Alzheimer's, and Type 2 diabetes. Its approach repairs cellular and mitochondrial membranes to slow disease progression, with early drug discovery programs led by an α-synuclein pore-targeting candidate for Parkinson's.
- Who are Amporin's investors?
- Amporin's investors include Kickfund.
- Where is Amporin headquartered?
- Amporin is headquartered in Basel, CH.